Dr Vityala Yethindra from Telangana, India, is the recipient of the MedEngage Award and Scholarship under the “Champion of the Champions” category – launched by Metropolis Healthcare Ltd. – awarded at MedEngage Scholarship Summit 2021.
Dr. Vityala Yethindra
“I am elated and humbled to be recognized,” Dr Yethindra said. “This is a great initiative and opportunity from Metropolis for talented medical students and doctors in India.”
As a researcher, Dr Yethindra proved that fluoxetine and doxycycline inhibit SARS-CoV-2 replication in-vitro; evaluated the safety and efficacy of umifenovir, heparin, itolizumab, and rivaroxaban in patients with COVID-19; and achieved positive results. He was the first to report and publish new and rare case reports on diseases such as epilepsy, neurofibromatosis, and ischemic stroke. He assisted in the development of remdesivir, which inhibits SARS-CoV and MERS-CoV in-vitro, and developed a VYTR hypothesis for the treatment of COVID-19. Remdesivir is a life-saving drug in many countries, including India.
Yethindra says that he is delighted and excited to receive this prestigious award: “At the end of the day, we all work for solidarity to succeed, irrespective of our profession. That is what we all expect even if our dreams, inspirations, and aspirations differ; our shared target is to further develop and succeed.”
Dr Vityala Yethindra shows promise as a future superstar in medical research.
Subscribe today by clicking the link and stay updated with the latest news!" Click here!
